Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus-Reference-Cited by-同舟云学术

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus

Published:2018-02-15 Issue:6 Volume:28 Page:986-992
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Ishii Tomonori¹,Tanaka Yoshiya²,Kawakami Atsushi³,Saito Kazuyoshi²,Ichinose Kunihiro³,Fujii Hiroshi⁴,Shirota Yuko⁴,Shirai Tsuyoshi⁴,Fujita Yoko⁴,Watanabe Ryu⁴,Chiu Shih-Wei¹,Yamaguchi Takuhiro¹,Harigae Hideo⁴

Affiliation:

1. Department of Clinical Research, Innovation and Education Center, Tohoku University Hospital, Miyagi, Japan;

2. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan;

3. Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;

4. Division of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Miyagi, Japan

Funder

Ministry of Health, Labour and Welfare

Astellas

Daiichi-Sankyo

Takeda

Bristol-Myers

Chugai

Abbvie

MSD

Pfizer

Eisai